The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in ...

International: Kennedy also gave Cassidy assurances over vaccines, as the 70-year-old environmental lawyer has long sown ...

Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...

The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.